| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RBP6; CRABP-II |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CRABP2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CRABP2抗体的参考文献，按简洁格式整理：
---
1. **标题**：Cellular retinoic acid-binding protein II (CRABP2) as a biomarker in triple-negative breast cancer
**作者**：Zhang Y, et al.
**摘要**：研究通过免疫组化发现CRABP2在三阴性乳腺癌组织中高表达，并与患者预后不良相关。使用特异性抗体验证其作为潜在治疗靶点的可行性。
2. **标题**：CRABP2 regulates nuclear receptor-mediated differentiation in human keratinocytes
**作者**：Sessler RJ, Blaner WS
**摘要**：利用CRABP2抗体进行Western blot和免疫荧光实验，证明CRABP2通过调控视黄酸信号通路参与表皮细胞分化，抗体特异性经敲除细胞验证。
3. **标题**：Prognostic significance of CRABP2 in ovarian cancer detected by monoclonal antibody-based assays
**作者**：Huang L, et al.
**摘要**：开发针对CRABP2的单克隆抗体，通过ELISA和免疫组化分析卵巢癌患者样本，发现CRABP2高表达与化疗耐药性显著相关。
---
注：以上文献信息为示例性质，具体引用时请核对真实文献来源及实验细节。如需实际文献，建议在PubMed或Web of Science中以“CRABP2 antibody”、“CRABP2 biomarker”等关键词检索。
Cellular retinoic acid-binding protein 2 (CRABP2) is a member of the intracellular lipid-binding protein family, primarily involved in mediating the biological effects of retinoic acid (RA), an active metabolite of vitamin A. CRABP2 facilitates the transport of RA from the cytoplasm to the nucleus, where it interacts with nuclear receptors like retinoic acid receptors (RARs) to regulate gene expression. This process is critical for cellular differentiation, proliferation, and apoptosis, particularly during embryonic development and tissue homeostasis.
CRABP2 antibodies are widely used in research to study its expression, localization, and function in physiological and pathological contexts. Elevated CRABP2 levels have been associated with several cancers, including breast, ovarian, and lung cancers, where it may promote tumor progression by enhancing RA signaling or through RA-independent pathways. These antibodies enable the detection of CRABP2 via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the exploration of its role as a potential biomarker or therapeutic target.
Commercial CRABP2 antibodies are typically raised against specific epitopes, such as recombinant proteins or synthetic peptides, and validated for specificity using knockout controls or siRNA-mediated knockdown. Researchers utilize these tools to investigate CRABP2's involvement in developmental disorders, cancer metastasis, and drug resistance mechanisms, contributing to advances in molecular diagnostics and targeted therapies.
×
